These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22268396)

  • 1. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
    Vona-Davis L; Rose DP
    Curr Diabetes Rev; 2012 Mar; 8(2):116-30. PubMed ID: 22268396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and Breast Cancer: Molecular Targets.
    Faria J; Negalha G; Azevedo A; Martel F
    J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between menopausal status and obesity in affecting breast cancer risk.
    Rose DP; Vona-Davis L
    Maturitas; 2010 May; 66(1):33-8. PubMed ID: 20181446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
    Fuentes-Mattei E; Velazquez-Torres G; Phan L; Zhang F; Chou PC; Shin JH; Choi HH; Chen JS; Zhao R; Chen J; Gully C; Carlock C; Qi Y; Zhang Y; Wu Y; Esteva FJ; Luo Y; McKeehan WL; Ensor J; Hortobagyi GN; Pusztai L; Fraser Symmans W; Lee MH; Yeung SC
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
    Ligibel JA; Strickler HD
    Am Soc Clin Oncol Educ Book; 2013; ():52-9. PubMed ID: 23714455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
    BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and breast cancer risk: a meta-analysis and critical literature review.
    Col NF; Ochs L; Springmann V; Aragaki AK; Chlebowski RT
    Breast Cancer Res Treat; 2012 Oct; 135(3):639-46. PubMed ID: 22847511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
    Patterson RE; Marinac CR; Natarajan L; Hartman SJ; Cadmus-Bertram L; Flatt SW; Li H; Parker B; Oratowski-Coleman J; Villaseñor A; Godbole S; Kerr J
    Contemp Clin Trials; 2016 Mar; 47():64-71. PubMed ID: 26706665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.
    Berstein LM; Vasilyev DA; Iyevleva AG; Boyarkina MP; Poroshina TE; Khadzhimba AS; Imyanitov EN
    Future Oncol; 2015; 11(5):759-70. PubMed ID: 25757680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Martin-Castillo B; Menendez JA
    Curr Mol Med; 2010 Oct; 10(7):674-91. PubMed ID: 20712585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin as an Anticancer Agent.
    Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
    Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does use of metformin protect against cancer in Type 2 diabetes mellitus?
    Bo S; Benso A; Durazzo M; Ghigo E
    J Endocrinol Invest; 2012 Feb; 35(2):231-5. PubMed ID: 22490993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
    Hankinson SJ; Fam M; Patel NN
    Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
    Adamia N; Virsaladze D; Charkviani N; Skhirtladze M; Khutsishvili M
    Georgian Med News; 2007 Apr; (145):52-5. PubMed ID: 17525501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metformin - new data for an "old", but efficient, safe and reliable antidiabetic drug].
    Winkler G
    Orv Hetil; 2016 Jun; 157(23):882-91. PubMed ID: 27233831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.